Fighting leukemia with “duel”-targeted therapy
Tríona Ní Chonghaile
Index: 10.1126/scitranslmed.aat3887
Full Text: HTML
Abstract
Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.
Latest Articles:
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
2018-04-11
[10.1126/scitranslmed.aao3003]
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
2018-04-11
[10.1126/scitranslmed.aan3311]
Spooked neutrophils unmask sepsis
2018-04-11
[10.1126/scitranslmed.aat3891]
Adult neurogenesis in humans: Dogma overturned, again and again?
2018-04-11
[10.1126/scitranslmed.aat3893]
2018-04-11
[10.1126/scitranslmed.aan8292]